NCT05873803View on ClinicalTrials.gov

The Study of GR1802 in Patients with Chronic Rhinosinusitis with Nasal Polyps

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

December 30, 2024

Conditions
Chronic Rhinosinusitis with Nasal Polyps
Interventions
BIOLOGICAL

GR1802 injection

150mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

BIOLOGICAL

placebo

0mg/1ml. 2 ml every two weeks Route of administration: Subcutaneous

Trial Locations (1)

100730

Beijing Tongren Hospital, Beijing

All Listed Sponsors
lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY